Phase 1/2Not yet recruiting
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)
A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)
- Sponsor
- Xynomic Pharmaceuticals, Inc. (Industry)
- Enrollment
- 221 planned
- Conditions
- Cancer; BRAF V600 Mutation; Melanoma; Colorectal Cancer; Thyroid Cancer; Nonsmall Cell Lung Cancer
- Interventions
- XP-102; Trametinib
- Ages
- adults, older adults
- Registry
- NCT05275374
Full record on ClinicalTrials.gov
From the registry
This is a first-in-human multi-center study which will be conducted in advanced malignant solid tumors patients. The solid tumor type is limited to melanoma, colorectal, non-small-cell lung, and thyroid cancer with positive BRAF V600 mutation. This study is divided into three stages: Phase Ia: a dose-escalation phase of XP-102; Phase Ib: a dose-escalation and sample size expansion phase of XP-102 plus trametinib; Phase IIa: an expansion phase of XP-102 plus trametinib.
Primary outcomes
- Characterize the safety of XP-102.
- Evaluate the pharmacokinetics of XP-102.
- Establish maximum tolerated dose of XP-102.
History
Study completion expected
Primary completion expected
Started
Last registry update
Registered